This section keeps you up-to-date on the latest news and upcoming public appearances of Lavery professionals.
News
-
Lavery assists Premier Parks LLC in the purchase of Calypso-Valcartier Group’s shares
On June 2, 2022, Calypso-Valcartier Group announced the sale of all of the shares of its two amusement parks, Village Vacances Valcartier located near Quebec City and Calypso, near Ottawa, and more specifically of the shares of the two parks’ operating corporations and their asset holding corporations. The assets of the two parks are now indirectly owned by EPR Properties, and they are operated by a Canadian subsidiary of Premier Parks, LLC. Our partners, André Vautour and France Camille De Mers, and their team assisted Premier Parks LLC in the due diligence of the parks’ assets and operations. They participated in structuring the new parks’ operating corporations, in the drafting of the share acquisition documentation of both the asset holding and operating corporations, and in the negotiation of all associated terms. The transaction was realized in collaboration with the Tennessee-based law firm Waller, a member, as is Lavery, of World Services Group, a worldwide network of premier law and other professional firms.
-
Catherine Deslauriers, Guy Lavoie, Éric Thibaudeau and Lavery named as a reference by the 2022 Canadian Occupational Safety – 5-Star Safety Lawyers & Law Firms
July 12, 2022 – Catherine Deslauriers, Guy Lavoie, Eric Thibaudeau and Lavery have been named as a reference in Occupational Health and Safety by Canadian Occupational Safety – 5-Star Safety Lawyers & Law Firms. To determine the best lawyers and law firms catering to the safety industry, Canadian Occupational Safety sourced feedback from safety leaders over a period of 15 weeks. COS’s research team began by conducting a survey with a wide range of safety officers to determine what companies value in the law firms they collaborate with.
-
Lavery supports the development of local e-commerce
On June 20, 2022, the Government of Québec and Plateforme Agora (now doing business as Le Panier Bleu) announced that Le Panier Bleu is transitioning to a private enterprise with the support of Quebec industry leaders. During the announcement, it was also confirmed that Le Panier Bleu will soon develop a transactional e-commerce platform making it possible to buy products from local merchants online. Lavery had the privilege of assisting Plateforme Agora in this round of financing and in Le Panier Bleu’s transition by providing advice on corporate financing, mergers and acquisitions, corporate law, intellectual property, commercial law in the field of technology and labour law. The Lavery team led by Étienne Brassard was composed of Jean-François Maurice, Isabelle Jomphe, Guillaume Laberge, Jessica Parent, Béatrice Bull, Isabelle Normand and Pamela Cifola.
-
-
Lexpert Recognizes Two Partners as Leading Infrastructures Lawyers in Canada
On June 16, 2022, Lexpert recognized the expertise of two of our partners in its 2022 Lexpert Special Edition: Infrastructure. Nicolas Gagnon and André Vautour now rank among Canada’s leaders in the area of infrastructure law. Nicolas Gagnon specializes in construction law and surety law. He counsels public and private sector clients, professional services firms and contractors as well as surety companies at every stage of construction projects. He advises clients with respect to the public bidding and procurement process, and is involved in the drafting of contract documents and the management of the work and any claims resulting therefrom. André Vautour practices in the fields of corporate and commercial law and is particularly interested in corporate governance, strategic alliances, joint ventures, investment funds and mergers and acquisitions of private corporations. He practises also in the field of technology law (drafting technology development and transfer agreements, licensing agreements, distribution agreements, outsourcing agreements, and e-commerce agreements).
-
Lexpert Recognizes Two Partners as Leading Technology Lawyers in Canada
On June 16, 2022, Lexpert recognized the expertise of two of our partners in its 2022 Lexpert Special Edition: Technology. Chantal Desjardins and André Vautour now rank among Canada’s leaders in the area of technology law. Chantal Desjardins is a partner, lawyer and trade-mark agent in Lavery’s intellectual property group. She contributes actively to the development of her clients’ rights in this field, which includes the protection of trade-marks, industrial designs, copyright, trade secrets, domain names and other related forms of intellectual property, in order to promote her clients’ business goals. André Vautour practices in the fields of corporate and commercial law and is particularly interested in corporate governance, strategic alliances, joint ventures, investment funds and mergers and acquisitions of private corporations. He practises also in the field of technology law (drafting technology development and transfer agreements, licensing agreements, distribution agreements, outsourcing agreements, and e-commerce agreements).
-
-
-
-
Lavery supports Domain Therapeutics in obtaining US $42M in financing
On May 10, 2022, Domain Therapeutics, a Franco-Canadian biopharmaceutical corporation specializing in research and development of innovative immuno-oncology treatments, announced the close of a US $42 million Series A financing round. This investment is a major step in the Franco-Canadian firm’s growth that aims to provide cancer patients with treatment solutions to overcome GPCR-mediated immunosuppression mechanisms. Mr. Alain Dumont, a partner at Lavery, had the privilege of supporting the corporation through this important transaction. Throughout his long-standing relationship with Domain Therapeutics, Mr. Dumont has lent his expertise to protect the company’s technologies and innovations by answering questions from investors, in particular. Lavery is immensely proud of Mr. Dumont’s work in securing this funding. — Domain Therapeutics, a biopharmaceutical company, based in France and Canada, is dedicated to discovering and developing novel medicine candidates targeting G-protein-coupled receptors (GPCRs), a key drug target class. The company focuses on producing high value-added immuno-oncology drug candidates.
-
-